Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

There is a need for efficacious and safe pain treatments for OA (osteoarthritis). The nerve growth factor (NGF) antibody tanezumab is associated with high efficacy, but when combined with chronic NSAID treatment shows an increased risk of rapidly progressive osteoarthritis (RPOA) in a small group of patients.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Osteoarthr. Cartil.

Title: Osteoarthritis and cartilage

Publisher: Elsevier BV

ISSN (Electronic): 1522-9653

ISSN (Print): 1063-4584

Publication date (Electronic): March 2019

Volume: 27

Issue: 3

Affiliations

[1 ] Nordic Bioscience, Herlev Hovedgade, DK-2730 Herlev, Denmark. Electronic address: mk@nordicbio.com.

[2 ] Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA. Electronic address: Kenneth.M.Verburg@pfizer.com.

[3 ] Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA. Electronic address: Christine.West@pfizer.com.

[4 ] Nordic Bioscience, Herlev Hovedgade, DK-2730 Herlev, Denmark. Electronic address: acbj@nordicbio.com.

[5 ] Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA. Electronic address: David.S.Keller@pfizer.com.

[6 ] Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA. Electronic address: Rosalin.Arends@pfizer.com.

Article

Publisher Item ID: S1063-4584(18)31554-1

DOI: 10.1016/j.joca.2018.12.001

PubMed ID: 30576794

SO-VID: ff3679a3-ffa4-4c75-b942-cd5d4e47a979

History

Keywords: THR,Biomarker,Clinical study,Osteoarthritis,RPOA2

Data availability:

Keywords: THR, Biomarker, Clinical study, Osteoarthritis, RPOA2

Comments

Comment on this article

scite_

Cited by 10

See all cited by

- Version 1